Skip to main content
Black Friday Sale - Get 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Despite getting a CRL, Scholar Rock expects to launch spinal muscular atrophy drug next year

Summary by endpoints.news
Scholar Rock said it intends to launch its spinal muscular atrophy drug apitegromab next year, even after the FDA rejected the drug over issues it found at a manufacturing site run by Novo Nordisk. ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

endpoints.newsendpoints.news

Despite getting a CRL, Scholar Rock expects to launch spinal muscular atrophy drug next year

Scholar Rock said it intends to launch its spinal muscular atrophy drug apitegromab next year, even after the FDA rejected the drug over issues it found at a manufacturing site run by Novo Nordisk. ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Monday, November 17, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Novo Nordisk icon

Novo Nordisk

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal